In the studies using second-generation tau tracers published to date, which are few [72–74], binding of [18F]RO-948 was elevated in medial temporal areas as well as more broadly throughout the cortex, including in the precuneus/posterior cingulate, lateral parietal and occipital lobes, and prefrontal cortex, in four AD patients in comparison to six healthy controls [72]. This evidence concerns the gene MAPT and Alzheimer disease.